Tenax Therapeutics (Tenax Therapeutics) Beginning Cash Position : $9.79 Mil (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Beginning Cash Position?

Tenax Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was $9.79 Mil.

Tenax Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 ($13.39 Mil) to Dec. 2023 ($11.14 Mil) and declined from Dec. 2023 ($11.14 Mil) to Mar. 2024 ($9.79 Mil).

Tenax Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($6.25 Mil) to Dec. 2022 ($5.58 Mil) and declined from Dec. 2022 ($5.58 Mil) to Dec. 2023 ($2.12 Mil).

Tenax Therapeutics Beginning Cash Position Historical Data

The historical data trend for Tenax Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Beginning Cash Position Chart

Tenax Therapeutics Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

12.37

4.91

6.25

5.58

2.12

Tenax Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															2.12	14.42	13.39	11.14	9.79

Tenax Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Tenax Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenax Therapeutics (Tenax Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517

Website

https://www.tenaxthera.com

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Executives

Robyn Hunter	director	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano	director, officer: CEO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	director	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich	officer: Chief Medical Officer	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck	director	2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl	director
James P. Mitchum	director	C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley	officer: Chief Executive Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502